Clinical trials: Drug-eluting Stent
Atherosclerosis, Coronary Artery Disease
XIENCE V® EXCEED: Evaluation of XIENCE V® Catheterization Lab Endpoints and Excellence in Delivery
This trial is to assess physician-determined XIENCE V® EECSS acute performance, deliverability and resource utilization in the catheterization lab during commercial use by various physicians with a range of coronary stenting…
- Trial name
- EXCEED (NCT00731237)
- Where
- 44 sites in United States
- Volunteers
- 2,517 people
- Sponsor
- Abbott Medical Devices
Cardiovascular Diseases, Vascular Disease
An Observational Registry Using Drug Eluting Stents (DES) in Patients in a Real-World Setting (DEScover Registry).
The DEScover Registry is designed to observe the results of using Drug Eluting Stents (DES) in patients in a real-world setting.
- Conditions
- Cardiovascular Diseases, Vascular Disease, Arterial Occlusive Disease, Arteriosclerosis
- Trial name
- DESCOVER (NCT00489320)
- Testing
- Cypher Stent
- Where
- United States
- Volunteers
- 7,759 people
- Sponsor
- Cordis US Corp.
Coronary Arteriosclerosis, Angina Unstable
Stents, Drug Eluting Stents, and CABG- Financial and Clinical Impact.
Options for coronary revascularization include stent implantation and coronary bypass surgery. Both modalities have their unique advantages and disadvantages in terms of clinical outcomes as well as financial impact on the…
- Conditions
- Coronary Arteriosclerosis, Angina Unstable, Myocardial Infarction
- Trial name
- NCT00394680
- Volunteers
- 700 people
- Sponsor
- Shaare Zedek Medical Center
Coronary Artery Disease
Evaluation of Effectiveness and Safety of BIOMATRIX Stent (IRIS-BIOMATRIX)
The objective of this study is to evaluate effectiveness and safety of BioMatrix stent in the "real world" daily practice as compared with first-generation drug-eluting stents (sirolimus- or paclitaxel-eluting stents).
- Trial name
- NCT01350778
- Where
- 20 sites in South Korea
- Volunteers
- 837 people
- Sponsor
- Seung-Jung Park
In-stent Coronary Artery Restenosis
In-stent Restenosis in Patients With Patent Previous Bare Metal Stent
Intra-coronary stents deployment reduces the rate of angiographic restenosis as compared to Balloon angioplasty. in-stent restenosis, usually defined as ≥50 percent diameter stenosis within previously deployed stent, is most…
- Trial name
- NCT01296399
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Rambam Health Care Campus
Coronary Artery Disease
Cynergy: the CYPHER-NEVO Registry
The purpose of this registry is to compare the safety and the performance of the NEVO™ Sirolimus-eluting Coronary Stent, once commercially available, to the CYPHER Select® Plus Sirolimus-eluting Coronary Stent in complex subjects…
- Trial name
- CYNERGY (NCT01106378)
- Where
- 3 sites in Brazil, South Korea and 1 more
- Volunteers
- 14,000 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
Deutsches Dual Therapy Stent Register
The DTS.DE registry is an initiative for the collection of high quality process and historical data of implantations with the COMBO Dual Therapy Stent in Germany.
- Trial name
- DTS Register (NCT02102997)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- OrbusNeich
Coronary Heart Disease
Economic Evaluation German Drug-Eluting Stent Registry
Since the advent of coronary stents, in-stent restenosis has proven to be the major limitation of interventional cardiology, occurring in as many as 30% of patients.
- Trial name
- NCT00866398
- Volunteers
- 3,973 people
- Sponsor
- Charite University, Berlin, Germany
Coronary Disease, Coronary Artery Disease
XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study
XIENCE V® India is a prospective, open-label, multi-center, observational, single-arm study to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- XIENCE V India (NCT00631228)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- 18 sites in India
- Volunteers
- 1,000 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, Ischemic Heart Disease
Sirolimus Eluting ORSIRO Stent Versus Biolimus-eluting NOBORI Stent
The aim of the Danish Organization for Randomized Trials with Clinical Outcome (SORT OUT) is to compare the safety and efficacy of the sirolimus eluting ORSIRO stent and the biolimus-eluting NOBORI stent in a population-based…
- Trial name
- SORT OUT VII (NCT01879358)
- Testing
- Drug-eluting stent
- Where
- Denmark
- Volunteers
- 2,314 people
- Sponsor
- Odense University Hospital
Coronary Artery Disease (CAD), Chronic Total Occlusion of Coronary Artery
Predictors and Long-term Incidence of In-stent Restenosis After Chronic Total Occlusion Percutaneous Coronary Intervention
The goal of this clinical trial is to describe the long-term (≥ 3 years) patency of coronary artery stents following chronic total occlusion percutaneous coronary intervention (CTO PCI).
- Conditions
- Coronary Artery Disease (CAD), Chronic Total Occlusion of Coronary Artery, Chronic Total Occlusion (CTO)
- Trial name
- NCT07473596
- Testing
- chronic total occlusion percutaneous coronary intervention (CTO PCI), coronary computed tomography angiography, invasive coronary angiography
- Where
- Finland
- Volunteers
- 294 people
- Sponsor
- Lauri Mansikkaniemi
Coronary Artery Disease
Effects of DES Platforms on Markers of Endothelial Damage and Inflammation
Percutaneous coronary intervention (PCI) with stenting may induce endothelial damage/dysfunction and inflammatory reactions, which in turn delay healing and endothelialization and may lead to restenosis and atherosclerosis within…
- Trial name
- PLATFORM (NCT01489202)
- Testing
- platinum chromium everolimus-eluting stent, cobalt chromium everolimus-eluting stent
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
Angina, Coronary Occlusion
XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
The objectives of the PMS are to observe the frequency, type, and degree of device deficiency to assure the safety of the new medical device (XIENCE PRIME) as well as to collect information on evaluation of the efficacy and…
- Conditions
- Angina, Coronary Occlusion, Coronary Artery Disease, Coronary Artery Stenosis
- Trial name
- NCT01721096
- Testing
- XIENCE PRIME - Long Length (LL), XIENCE PRIME - Core Size
- Where
- Japan
- Volunteers
- 536 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Registry to Evaluate the Efficacy of Zotarolimus-Eluting Stent
The objective of this study is to evaluate the safety and long-term effectiveness of coronary stenting with the zotarolimus eluting stent (ZES) and to determine clinical device and procedural success during commercial use of ZES.
- Trial name
- NCT00960908
- Testing
- Endeavor Resolute stents, Endeavor Sprint stent
- Where
- 19 sites in South Korea
- Volunteers
- 4,000 people
- Sponsor
- Seoul National University Hospital
AMI
Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent
The trial aims to evaluate 12-month long-term efficiency of Excel stent in the treatment of coronary heart disease and inhibition of restenosis after coronary artery stenting as well as a 12 months' long-term safety after the…
- Trial name
- CREATE (NCT00331578)
- Testing
- Excel drug-eluting coronary artery stent
- Volunteers
- 2,077 people
- Sponsor
- JW Medical Systems Ltd
Acute Coronary Syndrome, High Bleeding Risk
LEADERS FREE II: BioFreedom™ Pivotal Study
This study aims to confirm non-inferiority of the BioFreedom™ Drug Coated Stent to the Gazelle™ Bare Metal Stent arm of the Leaders Free study (NCT01623180) in high bleeding risk patients.
- Trial name
- NCT02843633
- Testing
- BioFreedom™ Drug Coated Coronary Stent System, Antiplatelet Drug
- Where
- 66 sites in United States, Canada and 5 more
- Volunteers
- 1,203 people
- Sponsor
- Biosensors Europe SA
Coronary Artery Disease
Korean Nationwide Multicenter Pooled Registry of Drug-Eluting Stents
The objective of this study is to evaluate the long-term efficacy and safety of coronary stenting with the various types of drug-eluting stents (DES) and to determine clinical device and procedural success during commercial use…
- Trial name
- Grand-DES (NCT03507205)
- Testing
- Biomatrix; Biomatrix Flex; Nobori, Xience Prime, Xience V/Promus; Cypher
- Where
- 37 sites in South Korea
- Volunteers
- 17,286 people
- Sponsor
- Seoul National University Hospital
Vessel Restenosis
Dexamethasone-Eluting Stent in Acute Coronary Syndrome to Prevent Restenosis
The major obstacle of the long- termed success of percutaneous coronary intervention (PCI) is the restenosis. Restenosis results from complex pathophysiological response of the vascular tissue to the balloon injury.
- Trial name
- NCT00190099
- Testing
- Dexamethasone-Eluting Stent
- Volunteers
- 40 people
- Sponsor
- Far Eastern Memorial Hospital
Coronary Artery Disease
The IRIS-Resolute Integrity (IRIS-Integrity)
This is a prospective, observational, cohort study to evaluate the relative efficacy and safety of Resolute Integrity stent compared to other (drug eluting stents) DES.
- Trial name
- NCT01392846
- Where
- 23 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- Seung-Jung Park
Hypertension, Coronary Artery Disease
Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial
Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was…
- Trial name
- NCT00139386
- Testing
- Candesartan
- Where
- Japan
- Volunteers
- 1,119 people
- Sponsor
- Kumamoto University